5
Native Valvular
Heart Disease
Table 6. Anticoagulation for Atrial Fibrillation (AF) in
Patients With VHD (2017)
Recommendations COR LOE
Anticoagulation with a vitamin K antagonist (VKA) is indicated
for patients with rheumatic mitral stenosis (MS) and AF.
I B-NR
Anticoagulation is indicated in patients with AF and a CHA
2
DS
2
-
VASc score of ≥2 with native aortic valve disease, tricuspid valve
(TV) disease, or mitral regurgitation (MR).
I C-LD
It is reasonable to use a direct oral anticoagulant (DOAC) as an
alternative to a VKA in patients with AF and native aortic valve
disease, tricuspid valve disease, or MR and a CHA
2
DS
2
-VASc
score of ≥2.
IIa C-LD
